Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Max EtonSchool of Human Sciences, University of Western Australia, Crawley, Western Australia, Australia.
Sophie StelmachSchool of Human Sciences, University of Western Australia, Crawley, Western Australia, Australia.
Pooja DeshpandeSchool of Human Sciences, University of Western Australia, Crawley, Western Australia, Australia.ORCID 0000-0002-6037-507X
Mark A PilkintonDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0009-0002-2085-0750
Wyatt J McDonnellDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-3859-2067
Anthony BoscoAsthma and Airway Disease Research Center, The BIO5 Institute, University of Arizona, Tucson, AZ, USA.ORCID 0000-0002-4335-615X
Simon A MallalInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.ORCID 0000-0002-7036-1309
Mina JohnSchool of Human Sciences, University of Western Australia, Crawley, Western Australia, Australia.ORCID 0000-0002-6429-0719
Spyros A KalamsDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Silvana GaudieriSchool of Human Sciences, University of Western Australia, Crawley, Western Australia, Australia.ORCID 0000-0001-6873-0198
Funding
Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Koethe · 2015 to 2026
$27.5M
VIROLOGY COREP30AI054999 · NIAID · VANDERBILT UNIVERSITY · PI HAINES, JONATHAN L · 2003 to 2011
$10.3M
PARTNERS/FENWAY/SHATTUCK CENTER FOR AIDS RESEARCHP30AI042851 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2000 to 2003
$5.7M
TCR GENE USAGE AND QUANTITATION OF HIV SPECIFIC CTLR01AI039966 · NIAID · VANDERBILT UNIVERSITY · PI KALAMS, SPYROS A · 1997 to 2006
Developing an effective HIV-1 vaccine is a global health priority, but HIV-1 mutational escape from T cells poses a challenge. While escape from human leukocyte antigen class I (HLA-I)-restricted CD8
Indexed as
CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHistocompatibility Antigens Class IIHIV-1HIV InfectionsHumansHistocompatibility Antigens Class II
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
HIV-1 adapts to HLA class II-associated selection pressure exerted by CD4 · full record | OpenQuestion